Made With Uberflip Content Marketing

Latest Content

Insight provides timely coverage of news that influences the business strategies of the life science industry. It is also the source for up-to-date information on leading industry partnering events.

  • Barcelona biotech companies shine light on regional entrepreneurship

    Barcelona biotech companies shine light on regional entrepreneurship

    Investors are always on the lookout for innovative biotech startups, and the Catalonia, Spain biopharma cluster has plenty to offer in the way of innovation from among its member companies....

    Read
  • ×

    Download "Digital Medicine Connect" Whitepaper

    First Name
    Last Name
    Thank you! Enjoy!
    Error - something went wrong!
  • Increase the value of your asset: Think with the end in mind

    Increase the value of your asset: Think with the end in mind

    Developing a drug is a very long journey, therefore it is critical to define the destination upfront. The Target Product Profile is like a postcard of your desired destination. It informs the data...

    Read
  • What’s the deal with Immuno-oncology partnering?

    What’s the deal with Immuno-oncology partnering?

    Insight wanted to get the lay of the I/O landscape, so who better to speak with than Jeff Bockman, Vice President of Defined Health. Not only was Jeff kind enough to share his insights with us,...

    Read
  • Join us at the Inaugural Cell & Gene Exchange this May 2017

    Learn More
  • Why the connected patient is the killer app in the digital age of medicine

    Why the connected patient is the killer app in the digital age of medicine

    Guest article by Deb Kilpatrick, PhD, CEO at Evidation Health and Rich Milani, MD, FACC, FAHA, Chief Clinical Transformation Officer at Ochsner Health System If you search on the phrase “killer...

    Read
  • Barcelona’s GP Pharm considers partnering key to international expansion

    Barcelona’s GP Pharm considers partnering key to international expansion

    Barcelona is an attractive location for business and trade, and has experienced a revival in the biopharma sector in recent years with the outsourcing of innovation from pharma companies to...

    Read
  • Breaking down the “four walls” of patient care: What is the state of the digital medicine industry?

    Breaking down the “four walls” of patient care: What is the state of the digital medicine industry?

    Amid tirelessly pursuing possible partnerships and investment opportunities to bring revolutionary medical products to market at Biotech Showcase™ 2017 in San Francisco, global executives were...

    Read
  • Welcome to Barcelona—one of the most vibrant life sciences hubs in Europe

    Welcome to Barcelona—one of the most vibrant life sciences hubs in Europe

    Guest article by BIOCAT, the Bioregion of Catalonia After the great success of previous editions (2010 and 2013), the Bioregion of Catalonia is again hosting BIO-Europe Spring® 2017 (March 20–22),...

    Read
  • Pulse, prognosis and the press: Journalists discuss key biotech trends for 2017

    Pulse, prognosis and the press: Journalists discuss key biotech trends for 2017

    As the intensity of Biotech Week in San Francisco winds down, join our exclusive panel of all-star reporters for their unique take on the news, trends and issues that will reverberate in 2017 and...

    Read
  • Biotech Showcase™ 2017: Payer environment will impact biopharma prospects in 20174:24

    Biotech Showcase™ 2017: Payer environment will impact biopharma prospects in 2017

    An increased focus on the need to access and develop truly transformational medicines was a key theme in the hallway chatter at this year’s Biotech Showcase/JP Morgan Healthcare meetings. Michael Hay,

    Watch Video
  • Unmet needs, uncommon commitment: The shift toward investment in rare diseases

    Unmet needs, uncommon commitment: The shift toward investment in rare diseases

    Join biotech leaders, emerging innovators, investors and patient advocacy group reps for a candid, interactive and enlightening discussion about rare disease drug discovery and development. Read...

    Read
  • ×

    Download "Finding Finance" Industry report

    First Name
    Last Name
    Thank you!
    Error - something went wrong!
  • Digital medicine: Invest in innovation

    Digital medicine: Invest in innovation

    It’s too soon to say, definitively, whether digital medicine will be disruptive or adjunctive for drug developers or even the entire healthcare system. Even the business models are in flux. What...

    Read
  • Rare diseases, rare commitment

    Rare diseases, rare commitment

    Patients, their families and patient foundations are invaluable in helping drug developers understand the day-to-day realities of approx. 7,000 rare diseases (of which only 400 have therapies)....

    Read
  • Biotech Showcase™ 2017: J&J poised to establish no-strings-attached JLABS outside America8:28

    Biotech Showcase™ 2017: J&J poised to establish no-strings-attached JLABS outside America

    As Johnson & Johnson announced the establishment of its eighth JLABS facility, in collaboration with New York State and the New York Genome Center, Melinda Richter, head of Johnson & Johnson Innovatio

    Watch Video
  • Biotech Showcase™ 2017: Second Genome CEO predicts paradigm shift with microbiome discovery8:05

    Biotech Showcase™ 2017: Second Genome CEO predicts paradigm shift with microbiome discovery

    Microbiome discovery and development will trigger the next major paradigm shift in medicine, more profound than the discovery of recombinant DNA, Second Genome CEO Glenn Nedwin predicted in an intervi

    Watch Video
  • Biotech Showcase™ 2017: CBMG aims for large-scale CAR-T capacity9:36

    Biotech Showcase™ 2017: CBMG aims for large-scale CAR-T capacity

    Cellular Biomedicine Group (CBMG) CEO Bizuo (Tony) Liu differentiates plans for chimeric antigen receptor-T cell development in part by large-scale production in the company's home country, China. In

    Watch Video
  • Biotech Showcase™ 2017: MEI Pharma rides wave of interest in AML12:05

    Biotech Showcase™ 2017: MEI Pharma rides wave of interest in AML

    Following a Phase II release of data for its oral histone deacetylase (HDAC) inhibitor pracinostat in the tough-to-treat acute myeloid leukemia (AML), MEI Pharma CEO Dan Gold says he is optimistic hea

    Watch Video
  • Biotech Showcase™ 2017: Flexion gears up to commercialize Zilretta10:13

    Biotech Showcase™ 2017: Flexion gears up to commercialize Zilretta

    Following submission of new drug application of Zilretta (FX006) for knee osteoarthritis in mid-December 2016, Flexion Therapeutics CEO Mike Clayman is hoping for priority review of the filing, in add

    Watch Video
  • Finding the value of real-world evidence

    Finding the value of real-world evidence

    Real-world evidence isn’t about what happens in the clinic, but is just as important to your success. It’s the application of analytics to real-world data collected outside the realm of...

    Read
  • The renaissance of gene therapy

    The renaissance of gene therapy

    Gene therapy and gene editing are at the beginning of a renaissance, according to speakers at Biotech Showcase™ 2017. While sizeable challenges exist, they are being overcome, leaving the field...

    Read
  • The state of cell and gene therapy: Reimbursement and manufacturing dominate

    The state of cell and gene therapy: Reimbursement and manufacturing dominate

    The number of cell therapies in clinical trials has grown 21 percent since 2015, with more than 759 trials underway globally. With that growth it is time for the industry to get serious about...

    Read
  • Who gets funded? Imaginative companies!

    Who gets funded? Imaginative companies!

    The biotech industry needs a new approach that approximates the type of disruption that Uber brought to transportation and Amazon and eBay brought to retail sales. Instead of embracing those lean...

    Read
  • Realities of Rare Disease and the Role of Patient Investors

    Realities of Rare Disease and the Role of Patient Investors

    Guest post by Nicole Boice, Founder & CEO, Global Genes – Allies in Rare Disease Rare Disease represents the largest disease community on the planet!  With over 7,000 identified diseases,...

    Read
  • Digital Health Security: The Most Important Tradeoff Between Ease and Privacy

    Digital Health Security: The Most Important Tradeoff Between Ease and Privacy

    Guest post by Nicole Fisher, Founder & CEO at HHR Strategies, Inc., Forbes Contributor Wayne Gretzky always said it’s better to look where the puck is going, not where it is now. The introduction...

    Read
  • Thirteen young people bucking the odds, finding paths to break into biotech

    Thirteen young people bucking the odds, finding paths to break into biotech

    Guest post by Luke Timmerman, founder and editor of the Timmerman Report, and a regular contributor to Forbes and STAT News. Walking around San Francisco’s Union Square during biotech conference...

    Read
  • DIGITAL-MEDICINE-WHITEPAPER

    DIGITAL-MEDICINE-WHITEPAPER

    Read Flipbook
  • Industry pundit Joe Hage on medtech innovation in 2017

    Industry pundit Joe Hage on medtech innovation in 2017

    Joe Hage, a medical device marketing consultant, is well known in medtech circles. In particular, he runs one of the largest and possibly most successful LinkedIn groups, the “Medical Devices...

    Read
  • Digital Health: Smart Devices Were Just The Beginning

    Digital Health: Smart Devices Were Just The Beginning

    The connectivity that will be created by the convergence of computers and health will truly alter the way knowledge, technology and insights into the future revolutionize health care.

    Read
  • Pharma Industry Report: Top 10 Drugs

    Pharma Industry Report: Top 10 Drugs

    Read Flipbook
  • It’s all happening at Biotech Showcase™ Week

    It’s all happening at Biotech Showcase™ Week

    Guest post by Constantine Theodoropulos, President, GO Therapeutics Thankfully there is a holiday between now and Biotech Showcase™ Week in San Francisco (Jan 9–11), because we are going to need...

    Read
  • How Do Healthcare Investors and Payers Separate the Tools From the Toys?

    How Do Healthcare Investors and Payers Separate the Tools From the Toys?

      Guest post by Nicole Fisher, Founder & CEO at HHR Strategies, Inc., Forbes Contributor The healthcare sector does not behave like other industries when it comes to money. First, attracting...

    Read
  • Partnering in the Pharma World: BIO-Europe® and industry trends 2012-2015

    Partnering in the Pharma World: BIO-Europe® and industry trends 2012-2015

    Read Flipbook
  • Breaking news:  Creating a healthcare futures market

    Breaking news: Creating a healthcare futures market

    Dennis Purcell, founder and senior advisor of Aisling Capital LLC, and co-founder of Poliwogg, is creating a futures market for healthcare, mirroring healthcare consumption from diagnosis to...

    Read
  • Lifetime trends in biopharmaceutical innovation: Recent evidence and implications

    Lifetime trends in biopharmaceutical innovation: Recent evidence and implications

    Guest blog post by Murray Aitken, Executive Director of the QuintilesIMS Institute Adequate returns on life sciences investments underpin the sustainability of the innovation lifecycle.   And...

    Read
  • Biotech Showcase™ 2017: Reinventing Arena to focus on Phase II clinical candidates6:06

    Biotech Showcase™ 2017: Reinventing Arena to focus on Phase II clinical candidates

    In the six months after joining Arena Pharmaceuticals as CEO, Dr. Amit Munshi has been busy: reducing the company’s commitment to obesity drug Belviq, which it has partnered with Eisai; spinning out t

    Watch Video
  • Biotech Showcase™ 2017: PhaseRx makes more noise than silence with mRNA delivery8:05

    Biotech Showcase™ 2017: PhaseRx makes more noise than silence with mRNA delivery

    Having ditched RNA silencing in 2012, PhaseRx president and CEO Dr. Robert Overell explains to Mike Ward, global director of content at Informa Pharma Intelligence’s insights portfolio, how delivering

    Watch Video
  • Biotech Showcase™ 2017: Janssen focuses cardiometabolic R&D on prevention, cure and interception9:11

    Biotech Showcase™ 2017: Janssen focuses cardiometabolic R&D on prevention, cure and interception

    With readouts in important trials of key drugs Invokana and Xarelto on the horizon, Dr. James F. List, Global Therapeutic Area Head of Cardiovascular and Metabolism, has plenty of reasons for insomnia

    Watch Video
  • Biotech Showcase™ 2017: Double-barreled approach doubles survival times in recurrent glioma patients7:53

    Biotech Showcase™ 2017: Double-barreled approach doubles survival times in recurrent glioma patients

    Brain cancer remains one of the deadliest diseases, and little to no effective treatments exist. Marty Duvall, newly appointed CEO of San Diego-based gene therapy technology company Tocagen, tells Mik

    Watch Video
  • UK Establishment upbeat about Brexit’s effect on British life science industry

    UK Establishment upbeat about Brexit’s effect on British life science industry

    Brexit may no longer be at the top of popular news, but it continues to be a key concern for biopharma companies in post-Brexit 2017. The sentiment of key players from the UK life sciences from a...

    Read
  • Finding Finance: Pharma, Biotech & Medtech Capital Raising 2016

    Finding Finance: Pharma, Biotech & Medtech Capital Raising 2016

    Read Flipbook
  • Taming the Wild West of digital medicine

    Taming the Wild West of digital medicine

    The new paradigm of healthcare is widely becoming known as “The Digital Health Revolution,” referring to medical technology advancements so great that when combined with wearables, medication...

    Read
  • Investors’ appetite for the life sciences continued in 2016

    Investors’ appetite for the life sciences continued in 2016

    Guest post by Doro Shin, Thought Leadership Manager at Informa Pharma Intelligence While 2015 was a record year for investments within the life sciences industry, investors became wary toward the...

    Read
  • Inositec CEO on 2017 financing plans

    Inositec CEO on 2017 financing plans

    Inositec is developing innovative new drugs using its proprietary Inositune technology to adjust the properties of inositol phosphate analogs, says CEO Mattias Ivarsson. Read more » Related...

    Read
  • Biotech Showcase™ 2017: ProNAI defects from oligos to DDR as Sierra Oncology10:37

    Biotech Showcase™ 2017: ProNAI defects from oligos to DDR as Sierra Oncology

    Sierra Oncology president and CEO Dr. Nick Glover tells Mike Ward, Informa Pharma Intelligence insight global director of content, how the company is rebranding itself from its former incarnation ProN

    Watch Video
  • Deciphera CEO on tackling cancer drug resistance

    Deciphera CEO on tackling cancer drug resistance

    CEO Michael Taylor talks about Deciphera Pharmaceuticals’ cell-signaling technology and explains the company's strategy of addressing drug resistance in cancer by blocking multiple cancer...

    Read
  • Biotech Showcase™ 2017: Chinese capital accesses Western innovation to create homegrown industry8:15

    Biotech Showcase™ 2017: Chinese capital accesses Western innovation to create homegrown industry

    With the Chinese market growing at 10–15% a year, it is poised to be world’s largest by 2026. Tony Chu, co-founder and managing partner at consultants TPP Healthcare, explains to Mike Ward, global dir

    Watch Video
  • Biotech Showcase™ 2017: Advancing neurokinin receptor antagonists in respiratory and women’s health6:18

    Biotech Showcase™ 2017: Advancing neurokinin receptor antagonists in respiratory and women’s health

    Starting the year with a cash injection of GDP 23 million, 2012 GSK spin-out NeRRe Therapeutics intends to advance its neurokinin receptor antagonist pipeline towards late-stage clinical development.

    Watch Video
  • Biotech Showcase™ 2017: Q BioMed plans to accelerate up to four more assets6:07

    Biotech Showcase™ 2017: Q BioMed plans to accelerate up to four more assets

    Established in June 2015, Q BioMed, the NYC-based biomedical acceleration development company, is looking to add three to four more assets to its portfolio. Company founder and CEO, Denis Corin, outli

    Watch Video
  • Biotech Showcase™ 2017: Catabasis pursues bifunctional mutation-agnostic approach to DMD7:09

    Biotech Showcase™ 2017: Catabasis pursues bifunctional mutation-agnostic approach to DMD

    Using its safely metabolized and rationally targeted (SMART) linker platform, Catabasis has identified an NF-κB inhibitor—edasalonexent—as a potential Duchenne muscular dystrophy (DMD) treatment. Spea

    Watch Video
  • Biotech Showcase™ 2017: Grünenthal looks beyond pain for transformative deals8:15

    Biotech Showcase™ 2017: Grünenthal looks beyond pain for transformative deals

    Speaking at the 2017 Biotech Showcase™ in San Francisco, Gruenenthal CEO Gabriel Baertschi reveals his ambition to grow the company from its current EUR 1.4 billion a year revenues to EUR 2 billion by

    Watch Video
  • Peter Fong on Genentech’s science shopping list, recent BioNtech deal

    Peter Fong on Genentech’s science shopping list, recent BioNtech deal

    Peter Fong explains Genentech's oncology focus, seeking the best science and how a typical biotech deal works for the company. Read more » Related Posts BioNTech’s Sean Marett explains Genentech...

    Read
  • Atlantic Healthcare outlines filing plans

    Atlantic Healthcare outlines filing plans

    CEO Toby Wilson Waterworth of Atlantic Healthcare discusses the company's recent fundraising and outlines Atlantic's development and filing plans for lead product, alicaforsen. Read more...

    Read
  • Vaximm seeks pharma partners for T-cell/checkpoint inhibitor combos

    Vaximm seeks pharma partners for T-cell/checkpoint inhibitor combos

    Dr. Matthias Schroff, the new CEO of privately-held Swiss vaccines company Vaximm, talks about how the company is differentiating itself in the crowded immuno-oncology development space. Read...

    Read
  • InflaRX CEO highlights pipeline goals

    InflaRX CEO highlights pipeline goals

    InflaRX is developing highly specific monoclonal antibodies targeting activation products of the complement system and has made breakthrough discoveries in anti-C5a antibody generation, according...

    Read
  • How are regulatory changes affecting early stage R&D in China?

    How are regulatory changes affecting early stage R&D in China?

    Darren Ji discusses the recent crackdown on clinical data quality by the China FDA and regulatory changes for early stage R&D in the region. Read more » Related Posts Motif’s CEO on business leap...

    Read
  • Dimerix CEO explains company’s different drug combo R&D strategy

    Dimerix CEO explains company’s different drug combo R&D strategy

    Kathy Harrison, CEO of Australian biotech Dimerix, talks about the company's unusual business model, Dimerix's Receptor-Heteromer Investigation Technology (HIT) platform and how it is used by the...

    Read
  • Denali deal and F-star’s innovative asset centric business model

    Denali deal and F-star’s innovative asset centric business model

    Jane Dancer, chief business officer at F-star, discusses F-star's asset-centric business strategy and the company's recent deal with Denali Therapeutics. Read more » Related Posts BioNTech’s Sean...

    Read
  • Freshly-appointed Auspherix CEO highlights new antibiotic class

    Freshly-appointed Auspherix CEO highlights new antibiotic class

    Auspherix’s newly-appointed CEO talks about the science behind the company’s gram-negative targeting new antibiotic class and the development timeline for the company's preclinical assets. Read...

    Read
  • BioNTech’s Sean Marett explains Genentech deal rationale

    BioNTech’s Sean Marett explains Genentech deal rationale

    Chief operating officer of BioNTech, Sean Marett, talks about the German firm's recent co-development deal with Roche company, Genentech. Read more » Related Posts What alliance opportunities...

    Read
  • Karus CEO highlights niche indications for oncology innovation

    Karus CEO highlights niche indications for oncology innovation

    Karus Therapeutics CEO, Simon Kerry, discusses the company’s cancer-focused pipeline and its strategy of targeting niche cancer indications. Read more » Related Posts CEVEC CEO talks US deals to...

    Read
  • Neovacs CEO outlines clinical timeline for lupus drug

    Neovacs CEO outlines clinical timeline for lupus drug

    Miguel Sieler, CEO of 25-year-old French vaccines company Neovacs, discusses the company's early lead in immunostimulation research and innovative early-stage research in the Type 1 diabetes...

    Read
  • AiCuris seeks partners for antibacterial programs

    AiCuris seeks partners for antibacterial programs

    AiCuris CEO Holger Zimmermann talks about the company's journey to becoming a clinical biotech company since being spun out of Bayer AG as a small research group a decade ago. Read more » Related...

    Read
  • loading
    Loading More...